AARTIDRUGS:NSE-Aarti Drugs Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 622.75

Change

-9.50 (-1.50)%

Market Cap

INR 58.57B

Volume

0.13M

Avg Analyst Target

INR 800.00 (+28.46%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide, sodium salt, benzyl nicotinate, bisphenol ? C, bisphenol ? C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Additionally, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India. Address: Mahendra Industrial Estate, Mumbai, India, 400 022

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+11.60 (+1.43%)

INR1,951.86B 32.54 21.03
DIVISLAB:NSE Divi's Laboratories Limited

+130.45 (+2.60%)

INR1,332.36B 65.02 42.88
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-3.50 (-0.08%)

INR773.97B 45.24 20.08
PEL:NSE Piramal Enterprises Limited

+3.15 (+0.12%)

INR638.12B 46.48 11.38
CADILAHC:NSE Cadila Healthcare Limited

+0.40 (+0.08%)

INR520.88B 22.97 16.53
ALKEM:NSE Alkem Laboratories Limited

+34.95 (+0.95%)

INR441.89B 27.09 20.10
LUPIN:NSE Lupin Limited

+7.05 (+0.76%)

INR422.18B 25.63 13.58
AUROPHARMA:NSE Aurobindo Pharma Limited

+3.10 (+0.44%)

INR412.21B 7.74 4.84
LAURUSLABS:NSE Laurus Labs Limited

+10.30 (+1.82%)

INR303.08B 28.89 18.02
IPCALAB:NSE Ipca Laboratories Limited

-17.15 (-0.78%)

INR277.92B 27.73 19.80

ETFs Containing AARTIDRUGS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.27% 18% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.27% 18% F 8% F
Trailing 12 Months  
Capital Gain -3.20% 22% F 6% F
Dividend Return 0.39% 26% F 13% F
Total Return -2.81% 23% F 6% F
Trailing 5 Years  
Capital Gain -7.19% 30% F 39% F
Dividend Return 0.82% 20% F 9% F
Total Return -6.37% 30% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 25.52% 60% D- 72% C-
Dividend Return 0.20% 23% F 16% F
Total Return 25.72% 58% F 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 106.42% 20% F 15% F
Risk Adjusted Return 24.16% 29% F 50% F
Market Capitalization 58.57B 63% D 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.15 53% F 44% F
Price/Book Ratio 6.18 29% F 18% F
Price / Cash Flow Ratio 37.83 19% F 15% F
EV/EBITDA 15.44 50% F 43% F
Management Effectiveness  
Return on Equity 35.81% 97% A+ 96% A
Return on Invested Capital 26.54% 94% A 95% A
Return on Assets 14.48% 87% B+ 95% A
Debt to Equity Ratio 16.15% 26% F 46% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.05 32% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.